SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
bluebird bio, Inc. (BLUE) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+175.5%).
- Analyst consensus target $13.69 (+175.5% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 38/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BLUE
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.57
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-24.84
Book Value / Share$0.00
Revenue / Share$8.65
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$13.69 (+175.5%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-4.81 |
$14.08M |
$-166.78M |
-1184.6% |
| 2016 |
$-7.07 |
$6.16M |
$-263.51M |
-4281.2% |
| 2017 |
$-7.71 |
$35.43M |
$-335.64M |
-947.4% |
| 2018 |
$-10.68 |
$54.58M |
$-555.63M |
-1018% |
| 2019 |
$-14.31 |
$44.67M |
$-789.61M |
-1767.5% |
| 2020 |
$-9.95 |
$250.73M |
$-618.7M |
-246.8% |
| 2021 |
$-8.16 |
$3.66M |
$-562.64M |
-15364.2% |
| 2022 |
$-3.39 |
$3.6M |
$-266.58M |
-7411.1% |
| 2023 |
$-1.93 |
$29.5M |
$-211.91M |
-718.4% |
| 2024 |
$-24.84 |
$83.81M |
$-240.72M |
-287.2% |
